Cargando…

UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma

Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib has been studied in trials for melanoma, lymphoma, glioblastoma, breast cancer, and other cancers. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qingqing, Liu, Ya-nan, Wang, Jing, Hu, Yingying, Hu, Jinyu, Xu, Ren-ai, Shao, Liu, Chen, Lianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237521/
https://www.ncbi.nlm.nih.gov/pubmed/35774599
http://dx.doi.org/10.3389/fphar.2022.914733
_version_ 1784736812385697792
author Li, Qingqing
Liu, Ya-nan
Wang, Jing
Hu, Yingying
Hu, Jinyu
Xu, Ren-ai
Shao, Liu
Chen, Lianguo
author_facet Li, Qingqing
Liu, Ya-nan
Wang, Jing
Hu, Yingying
Hu, Jinyu
Xu, Ren-ai
Shao, Liu
Chen, Lianguo
author_sort Li, Qingqing
collection PubMed
description Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib has been studied in trials for melanoma, lymphoma, glioblastoma, breast cancer, and other cancers. In this study, a highly sensitive and rapid ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) technology was applied to the quantitative methodology and pharmacokinetic analysis of voxtalisib in rat plasma. After protein precipitation of the analyte by acetonitrile, the chromatographic separation was performed by gradient elution on an Acquity BEH C18 column (2.1 mm × 50 mm, 1.7 μm) with acetonitrile (solvent A) and 0.1% formic acid (solvent B) as the mobile phase. In the positive ion mode, the mass transfer detection of the analyte and IS was m/z 270.91 > 242.98 and m/z 572.30 > 246.10, respectively. In the concentration range of 1–2000 ng/ml, a good linear relationship of voxtalisib was successfully established by the UPLC-MS/MS technology, and the lower limit of quantification (LLOQ) of the analyte was identified as 1 ng/ml. Intra-day and inter-day precisions for voxtalisib were 7.5–18.7% and 13.0–16.6%, respectively, and the accuracies were in the ranges of −14.0–2.0% and −7.2–3.1%, respectively. The matrix effect, extraction recovery, carryover and stability of the analyte were all in compliance with the acceptance criteria of bioassays recommended by FDA. Finally, the pharmacokinetic profile of the analyte had been availably studied by the UPLC-MS/MS bio-analytical method after rats were treated by intragastric administration with voxtalisib (5 mg/kg). The results indicated that the UPLC-MS/MS technology can effectively and quickly quantify the analyte, and this method can also be used for the pharmacokinetic study of voxtalisib, which can provide reference for the optimization of clinical drug management in the later period.
format Online
Article
Text
id pubmed-9237521
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92375212022-06-29 UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma Li, Qingqing Liu, Ya-nan Wang, Jing Hu, Yingying Hu, Jinyu Xu, Ren-ai Shao, Liu Chen, Lianguo Front Pharmacol Pharmacology Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib has been studied in trials for melanoma, lymphoma, glioblastoma, breast cancer, and other cancers. In this study, a highly sensitive and rapid ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) technology was applied to the quantitative methodology and pharmacokinetic analysis of voxtalisib in rat plasma. After protein precipitation of the analyte by acetonitrile, the chromatographic separation was performed by gradient elution on an Acquity BEH C18 column (2.1 mm × 50 mm, 1.7 μm) with acetonitrile (solvent A) and 0.1% formic acid (solvent B) as the mobile phase. In the positive ion mode, the mass transfer detection of the analyte and IS was m/z 270.91 > 242.98 and m/z 572.30 > 246.10, respectively. In the concentration range of 1–2000 ng/ml, a good linear relationship of voxtalisib was successfully established by the UPLC-MS/MS technology, and the lower limit of quantification (LLOQ) of the analyte was identified as 1 ng/ml. Intra-day and inter-day precisions for voxtalisib were 7.5–18.7% and 13.0–16.6%, respectively, and the accuracies were in the ranges of −14.0–2.0% and −7.2–3.1%, respectively. The matrix effect, extraction recovery, carryover and stability of the analyte were all in compliance with the acceptance criteria of bioassays recommended by FDA. Finally, the pharmacokinetic profile of the analyte had been availably studied by the UPLC-MS/MS bio-analytical method after rats were treated by intragastric administration with voxtalisib (5 mg/kg). The results indicated that the UPLC-MS/MS technology can effectively and quickly quantify the analyte, and this method can also be used for the pharmacokinetic study of voxtalisib, which can provide reference for the optimization of clinical drug management in the later period. Frontiers Media S.A. 2022-06-14 /pmc/articles/PMC9237521/ /pubmed/35774599 http://dx.doi.org/10.3389/fphar.2022.914733 Text en Copyright © 2022 Li, Liu, Wang, Hu, Hu, Xu, Shao and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Qingqing
Liu, Ya-nan
Wang, Jing
Hu, Yingying
Hu, Jinyu
Xu, Ren-ai
Shao, Liu
Chen, Lianguo
UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
title UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
title_full UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
title_fullStr UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
title_full_unstemmed UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
title_short UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
title_sort uplc-ms/ms technology for the quantitative methodology and pharmacokinetic analysis of voxtalisib in rat plasma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237521/
https://www.ncbi.nlm.nih.gov/pubmed/35774599
http://dx.doi.org/10.3389/fphar.2022.914733
work_keys_str_mv AT liqingqing uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma
AT liuyanan uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma
AT wangjing uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma
AT huyingying uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma
AT hujinyu uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma
AT xurenai uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma
AT shaoliu uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma
AT chenlianguo uplcmsmstechnologyforthequantitativemethodologyandpharmacokineticanalysisofvoxtalisibinratplasma